Basic info
Industry
biotechnology
Sectors
Biotechnology
Program a patient's cells to produce antibodies
Health Care
Scope of applicability extensive; for use in many diseases
Therapeutics
Enables an entire new set of treatments options for patients
enzymes
Patient convenience; eliminates frequent needle injections
Life Science
Date founded
2009
Funding rounds raised
Total raised
$20M
from 12 investors over 12 rounds
I
Immusoft Corporation raised $467K on September 25, 2020
Investors: National Institutes of Health
I
Immusoft Corporation raised $4.5M on September 25, 2020
Investors: Ikarian Capital LLC and Breakout Ventures
I
Immusoft Corporation raised $20M on January 3, 2019
Investors: Bios Partners, DEFTA Partners, GRIDS Capital, RBV Capital and Breakout Ventures
I
Immusoft Corporation raised $3M on January 5, 2018
Investors: EQx Fund and Invariantes Fund
I
Immusoft Corporation raised $2.7M on November 7, 2016
Investors: Breakout Ventures
I
Immusoft Corporation raised $2.4M on August 21, 2014
Investors: Founders Fund